MIRA: MIRA Pharmaceuticals Inc. Stocks News on October 29, 2025

MIRA

ACCESS Newswire

5 days ago

MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication

MIRA

MT Newswires

13 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

MIRA

MT Newswires

13 days ago

Top Midday Gainers

MIRA

MT Newswires

13 days ago

Mira Pharmaceuticals Says Oral Mira-55 Outperforms Injected Morphine in New Preclinical Data

MIRA

ACCESS Newswire

13 days ago

MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain

MIRA

ACCESS Newswire

4 months ago

MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition

MIRA

Benzinga

4 months ago

EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study

MIRA

ACCESS Newswire

4 months ago

MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects

MIRA

Zacks Small Cap Research

4 months ago

MIRA Announces Positive Test Results from Acquisition

MIRA

ACCESS Newswire

4 months ago

MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology

MIRA

Zacks Small Cap Research

4 months ago

MIRA Gets Validation from Journal

MIRA

ACCESS Newswire

5 months ago

MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program

MIRA

Zacks Small Cap Research

5 months ago

MIRA Releases Financials as Research Continues

MIRA

Market Exclusive

6 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

MIRA

TipRanks

6 months ago

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

MIRA

ACCESS Newswire

6 months ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

MIRA

Benzinga

6 months ago

EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million

MIRA

ACCESS Newswire

6 months ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

MIRA

Benzinga

6 months ago

EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study

MIRA

Zacks Small Cap Research

6 months ago

MIRA Sets Up Success With Stellar Safety Results

Psychedelic: Clearmind completes clinical site initiations for AUD trial

MIRA

TipRanks

6 months ago

Psychedelic: Clearmind completes clinical site initiations for AUD trial

MIRA

ACCESS Newswire

6 months ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA

Zacks Small Cap Research

6 months ago

MIRA Pain Treatment Expands Market Size Potential

MIRA

MT Newswires

6 months ago

Mira Says Diabetes Treatment Ketamir-2 Shows Significant Reduction in Neuropathic Pain Symptoms in Animal Model

MIRA

ACCESS Newswire

6 months ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

MIRA

Benzinga

6 months ago

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

MIRA

Zacks Small Cap Research

6 months ago

MIRA Continues Positive Testing Run

MIRA

TipRanks

7 months ago

Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2

MIRA

ACCESS Newswire

7 months ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA

Zacks Small Cap Research

7 months ago

MIRA Enrolls Patients Amid Rapid Progress

Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit

MIRA

TipRanks

7 months ago

Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit

MIRA

MT Newswires

7 months ago

Mira Pharmaceuticals Signs LOI to Acquire Skny Pharmaceuticals

MIRA

ACCESS Newswire

7 months ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

MIRA

Benzinga

7 months ago

EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug

MIRA

Zacks Small Cap Research

7 months ago

MIRA Makes Significant Acquisition and Boosts Capital

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

MIRA

TipRanks

8 months ago

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

MIRA

MT Newswires

8 months ago

Mira Pharmaceuticals Develops Topical Formulation of Ketamir-2 for Pain Relief

MIRA

Zacks Small Cap Research

8 months ago

MIRA Makes Another Pain Management Stride

MIRA

ACCESS Newswire

8 months ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA

ACCESS Newswire

8 months ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIRA

Benzinga

8 months ago

EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

MIRA

Zacks Small Cap Research

8 months ago

MIRA Announces Approval of Important Testing

MIRA

Simply Wall St.

10 months ago

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation

Memecoin Degens Raise Millions for Rare Cancer Research After a Father’s Plea

MIRA

CoinDesk

10 months ago

Memecoin Degens Raise Millions for Rare Cancer Research After a Father’s Plea

MIRA

ACCESSWIRE

10 months ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA

Benzinga

10 months ago

EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment

MIRA

Zacks Small Cap Research

10 months ago

MIRA Makes Major Strides

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA

Benzinga

a year ago

EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain

MIRA

ACCESSWIRE

a year ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA

Zacks Small Cap Research

a year ago

MIRA Continues Solid Financial Management

MIRA

GuruFocus.com

a year ago

MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials

MIRA

Benzinga

a year ago

MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

MIRA

Market Exclusive

a year ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA

Zacks Small Cap Research

a year ago

MIRA Continues to Post Outstanding Test Results

MIRA

MT Newswires

a year ago

MIRA Pharma Says Ketamir-2 Achieved 100% Neuropathic Pain Reversal in Preclinical Models

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

MIRA

Zacks Small Cap Research

a year ago

MIRA Makes Impressive Progress

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA

MT Newswires

a year ago

MIRA Pharmaceuticals Selects Neuropathic Pain as Initial Indication of Ketamir-2

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA

MT Newswires

a year ago

MIRA Pharmaceuticals Shares Surge Pre-Bell on 'Significant' Ketamir-2 Study Data

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

MIRA

Zacks Small Cap Research

a year ago

MIRA Announces Significant Test Results

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

MIRA

Zacks Small Cap Research

a year ago

MIRA Continues to Reveal Advances in Treatment

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

PayPal, Kellanova upgraded: Wall Street's top analyst calls

MIRA

The Fly

a year ago

PayPal, Kellanova upgraded: Wall Street's top analyst calls

MIRA

Benzinga

a year ago

Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action

MIRA

Simply Wall St.

a year ago

We're Not Very Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Rate

MIRA

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise Late Afternoon

MIRA

MT Newswires

a year ago

MIRA Pharmaceuticals Shares Quadruple on More 'Promising' Ketamir-2 Study Results

MIRA

Benzinga

a year ago

Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders

MIRA

ACCESSWIRE

a year ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

MIRA

Zacks Small Cap Research

a year ago

MIRA Posts More Positive Test Results

MIRA

Zacks Small Cap Research

a year ago

MIRA Announces More Positive Test Results

MIRA

ACCESSWIRE

a year ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

MIRA

PR Newswire

a year ago

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

MIRA

Zacks Small Cap Research

a year ago

MIRA Announces Positive Test Results

MIRA

PR Newswire

a year ago

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

MIRA

MT Newswires

a year ago

Sector Update: Health Care Stocks Retreat Wednesday Afternoon

MIRA

MT Newswires

a year ago

Mira Pharmaceuticals Says US DEA Finds Marijuana Analog a Non-Controlled Substance

MIRA

PR Newswire

a year ago

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

MIRA

Zacks Small Cap Research

a year ago

MIRA Announces Important Collaboration Potential

MIRA

PR Newswire

a year ago

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

MIRA

PR Newswire

a year ago

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

MIRA

Zacks Small Cap Research

a year ago

MIRA Focuses on Potential Game-Changing Drug Submission

MIRA

Zacks Small Cap Research

2 years ago

MIRA Making Strides Toward Breakthrough Treatment

MIRA

PR Newswire

2 years ago

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

MIRA

PR Newswire

2 years ago

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

MIRA

Simply Wall St.

2 years ago

Is MIRA Pharmaceuticals (NASDAQ:MIRA) In A Good Position To Deliver On Growth Plans?

MIRA

PR Newswire

2 years ago

MIRA Pharmaceuticals Provides Corporate Update

Charles River (CRL) to Report Q4 Earnings: What's in Store?

MIRA

Zacks

2 years ago

Charles River (CRL) to Report Q4 Earnings: What's in Store?

MIRA

Insider Monkey

2 years ago

11 Best Wine Stocks to Buy Now

/C O R R E C T I O N -- Nutex Health, Inc./

MIRA

PR Newswire

2 years ago

/C O R R E C T I O N -- Nutex Health, Inc./

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?

MIRA

Zacks

2 years ago

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?

Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update

MIRA

Zacks

2 years ago

Latest MIRA Pharmaceuticals Inc. (MIRA) News on October 29, 2025

Share on Social Networks: